Safety and tolerability of intermittent androgen deprivation therapy: A literature review

International Journal of Urology

Volumn 19, Issue 7, 2012, Pages 614-625

  Gruca, Damian ^a   Bacher, Peter ^c   Tunn, Ulf ^b  

^a ABBOTT GMBH AND CO KG   (Germany)

^b Prostate Center Offenbach   (Germany)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Androgen deprivation therapy; Intermittent; Prostate cancer; Quality of life; Safety; Tolerability

Indexed keywords

ANDROGEN;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; CARDIOVASCULAR DISEASE; HOT FLUSH; HUMAN; OBESITY; OSTEOLYSIS; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION;

ANEMIA; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; CARDIOVASCULAR DISEASES; FLUSHING; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OBESITY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 84862776297     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03001.x     Document Type: Review

References (51)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 1972; 22: 232-40.
2. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002; 60 (3 Suppl 1): 7-11. discussion 11-12.
3. Sciarra A, Cardi A, Di Silverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urol. Int. 2004; 72: 91-8.
4. Gomella LG. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev. Urol. 2009; 11: 52-60.
5. Kirby RS, Fitzpatrick JM, Clarke N. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009; 104: 1580-4.
6. Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin. Ther. 2009; 31 (Pt 2): 2312-31.
7. Heidenreich A, Bolla M, Joniau S etal. Guidelines on prostate cancer. [Cited 19 Apr 2011.] Available from URL:
8. Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol. Oncol. Clin. North Am. 2006; 20: 909-23.
9. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004; 64: 1182-6.
10. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 2006; 24: 4448-56.
11. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J. Natl. Compr. Canc. Netw. 2010; 8: 211-23.
12. Smith MR. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev. 2002; 21: 159-66.
13. Smith MR, Lee H, McGovern F etal. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-94.
14. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003; 8: 474-87.
15. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J. Sex. Med. 2010; 7: 2996-3010.
16. Potosky AL, Knopf K, Clegg LX etal. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J. Clin. Oncol. 2001; 19: 3750-7.
17. Rousseau L, Dupont A, Labrie F, Couture M. Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch. Sex. Behav. 1988; 17: 87-98.
18. Wein A, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh Urology, 10th edn. Elsevier Saunders, Philadelphia, PA, 2011.
19. Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol. Oncol. 2005; 23: 56-64.
20. Spetz AC, Zetterlund EL, Varenhorst E, Hammar M. Incidence and management of hot flushes in prostate cancer. J. Support. Oncol. 2003; 1: 263-6, 269-70, 272-3; discussion 267-8, 271-2.
21. Stone P, Hardy J, Huddart R, A'Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur. J. Cancer 2000; 36: 1134-41.
22. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br. J. Urol. 1997; 79: 933-41.
23. Wei JT, Gross M, Jaffe CA etal. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999; 54: 607-11.
24. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J. Clin. Endocrinol. Metab. 2006; 91: 1305-8.
25. Alibhai SM, Duong-Hua M, Sutradhar R etal. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol. 2009; 27: 3452-8.
26. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993; 71: 2782-90.
27. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 839-44; discussion 844-5.
28. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight (Abstract). BJU Int. 2007; 99 (Suppl 1): 19-22; discussion 23-4.
29. Tunn U, Eckhart O, Kienle E, Hillger H. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy - first results of a randomised prospective phase-III clinical trial (AUO study AP06/95; Abstract 86). Eur. Urol. 2003; 2: 24.
30. Sanchez-Salas R, Prapotnich D, Secin F etal. Intermittent androgen deprivation as secondary therapy for biochemical recurrence of localized prostate cancer (Abstract). American Urological Association May 14-19; Washington, DC, USA. 2011.
31. Calais da Silva FE, Bono AV, Whelan P etal. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur. Urol. 2009; 55: 1269-77.
32. de Leval J, Boca P, Yousef E etal. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin. Prostate Cancer 2002; 1: 163-71.
33. Tunn UW, Kurek R, Kienle E. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy (Abstract 1458). J. Urol. 2004; 171: 384.
34. Klotz L, O'Callaghan CJ, Ding K etal. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013 (Abstract 3). J. Clin. Oncol. 2011; 29 (Suppl 7).
35. Miller K, Steiner U, Lingnau A etal. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer (Abstract 5015). J. Clin. Oncol. 2007; 25: 5015.
36. Langenhuijsen JF, Schasfoort EMC, Heathcote P etal. Intermittent androgen suppression in patients with advanced prostate cancer: an update of the TULP survival data (Abstract 538). Eur. Urol. 2008; 7 (Suppl 3): 205.
37. Schasfoort E, Heathcote P, Lock T. Intermittent androgen suppression for the treatment of advanced prostate cancer (Abstract 1483). J. Urol. 2003; 169 (Suppl 4): 397.
38. Verhagen PCMS, Wissenburg LD, Wildhagen MF (eds) Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer (Abstract 541). 23rd Annual Congress of the European Association of Urology March 26-29; Milan, Italy. 2008.
39. Mottet N, Goussard N, Loulidi S, Wolff J. Intermittent Versus continuous maximal androgen blockade metastatic (D2) prostate cancer patients. A randomized trial (Abstract 44). Eur. Urol. 2009; 8 (Suppl 4): 131.
40. Malone S, Remco D, Gad P etal. Mature phase II study of intermittent androgen suppression therapy (IAS) in prostate cancer (PC): efficacy and long-term side effect profile. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57 (Suppl 2): S174.
41. Bouchot O, Lenormand L, Karam G etal. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur. Urol. 2000; 38: 543-9.
42. Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg SL. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin. Genitourin. Cancer 2008; 6: 46-52.
43. Spry NA, Kristjanson L, Hooton B etal. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur. J. Cancer 2006; 42: 1083-92.
44. Calais da Silva FE, Goncalves F, Santos A etal. Evaluation of quality of life, side-effects and duration of therapy in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation (Abstract 540). Eur. Urol. 2008; 7: 205.
45. Malone S, Perry G, Segal R, Dahrouge S, Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int. 2005; 96: 514-20.
46. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J. Natl. Cancer Inst. 2010; 102: 39-46.
47. Levine GN, D'Amico AV, Berger P etal. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121: 833-40.
48. Punnen S, Cooperberg M, Sadetsky N, Fuldeore M, Carroll P. editors. Causes of mortality following treatment for prostate cancer: what is the impact of androgen deprivation (Abstract 721). American Urological Association Annual meeting May 14-19; Washington, DC, USA. 2011.
49. Tunn U, Klotz L. Personal communication at the 12th Australasian Prostate Cancer Conference Melbourne 2011.
50. Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 2007; 70: 1104-8.
51. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur. Urol. 2010; 57: 49-59.